Vineet Laboratories Ltd (NSE: VINEETLAB, BSE: 543298) is a Hyderabad, Telangana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹75 Cr, it ranks #3,520 by market cap among the 6,137 Indian listed companies on FinBizNet, and #73 of 86 in Medicinal Chemicals and Botanical Products. At ₹36.23 (as of 25 Oct 2026), the share price is 27.5% below its 52-week high of ₹49.99 and 29.6% above its 52-week low of ₹27.96. The share price is down 10.5% over one year and down 5.9% over three months.
| Current Price | ₹36.23 |
|---|---|
| Market Cap | ₹75 Cr |
| NSE Symbol | VINEETLAB |
| BSE Code | 543298 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 38.8 |
| Return on Equity | 3.68% |
| Return on Assets | 3.52% |
| 52-Week Range | ₹27.96 – ₹49.99 |
| 1-Year Price Change | -10.5% |
| 3-Month Price Change | -5.9% |
| Beta (1Y) | 0.2 |
| Dividend Yield | 0.00% |
| Headquarters | Hyderabad, Telangana |
| Website | vineetlabs.co.in |
| Revenue | ₹19 Cr |
|---|---|
| Net Profit | ₹1 Cr |
| Net Margin | 3.9% |
| EPS (Basic) | ₹0.43 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API), intermediates, and fine chemicals primarily in India. The company offers intermediates of Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, Piroctone Olanine, and other API intermediates. It also provides fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, n-butyl lithium, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde. The company was incorporated in 2016 and is based in Hyderabad, India.
1. Drug Intermediates & Bulk Dugs-This segment engages in the research, development, and manufacture of active pharmaceutical ingredients and fine chemicals.
1. Active Pharmaceuticals Ingredient and Intermediates-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Vineet Laboratories Ltd | ₹75 Cr | 38.8 | 3.68% | ₹19 Cr | -10.5% |
Listed by market capitalisation. Ratios are shown for context only.
Vineet Laboratories Ltd is trading at ₹36.23, with a market capitalisation of ₹75 Cr.
Vineet Laboratories Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Vineet Laboratories Ltd has a P/E of 38.8 and a return on equity of 3.68%.
Vineet Laboratories Ltd is listed on the NSE under the symbol VINEETLAB and on the BSE under the scrip code 543298.
Vineet Laboratories Ltd's share price is down 10.5% over one year and down 5.9% over three months. Its 52-week range is ₹27.96 to ₹49.99.
In Q4 FY26, Vineet Laboratories Ltd reported revenue of ₹19 Cr and net profit of ₹1 Cr, with basic EPS of ₹0.43 (standalone, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.